153 related articles for article (PubMed ID: 20681062)
1. Antiretroviral vaginal gel shows promise against HIV.
Baleta A
Lancet; 2010 Jul; 376(9738):320. PubMed ID: 20681062
[No Abstract] [Full Text] [Related]
2. Drug concentrations after topical and oral antiretroviral pre-exposure prophylaxis: implications for HIV prevention in women.
Karim SS; Kashuba AD; Werner L; Karim QA
Lancet; 2011 Jul; 378(9787):279-81. PubMed ID: 21763939
[No Abstract] [Full Text] [Related]
3. Antiretrovirals for HIV prevention: translating promise into praxis.
Mayer KH
Lancet; 2011 Jul; 378(9787):206-8. PubMed ID: 21763922
[No Abstract] [Full Text] [Related]
4. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women.
Abdool Karim Q; Abdool Karim SS; Frohlich JA; Grobler AC; Baxter C; Mansoor LE; Kharsany AB; Sibeko S; Mlisana KP; Omar Z; Gengiah TN; Maarschalk S; Arulappan N; Mlotshwa M; Morris L; Taylor D;
Science; 2010 Sep; 329(5996):1168-74. PubMed ID: 20643915
[TBL] [Abstract][Full Text] [Related]
5. Genital Tenofovir Concentrations Correlate With Protection Against HIV Infection in the CAPRISA 004 Trial: Importance of Adherence for Microbicide Effectiveness.
Kashuba AD; Gengiah TN; Werner L; Yang KH; White NR; Karim QA; Abdool Karim SS
J Acquir Immune Defic Syndr; 2015 Jul; 69(3):264-9. PubMed ID: 26181703
[TBL] [Abstract][Full Text] [Related]
6. Battles with donors cloud Malawi's HIV prevention plan.
Donnelly J
Lancet; 2011 Jul; 378(9787):215-6. PubMed ID: 21770061
[No Abstract] [Full Text] [Related]
7. A second chance for microbicides.
Baleta A
Lancet; 2007 Jul; 370(9581):17-8. PubMed ID: 17632853
[No Abstract] [Full Text] [Related]
8. Study halted: no benefit seen from antiretroviral pill in preventing HIV in women.
Stephenson J
JAMA; 2011 May; 305(19):1952. PubMed ID: 21586708
[No Abstract] [Full Text] [Related]
9. After CAPRISA 004: time to re-evaluate the HIV lexicon.
Cates W
Lancet; 2010 Aug; 376(9740):495-6. PubMed ID: 20709216
[No Abstract] [Full Text] [Related]
10. High medication adherence during periconception periods among HIV-1-uninfected women participating in a clinical trial of antiretroviral pre-exposure prophylaxis.
Matthews LT; Heffron R; Mugo NR; Cohen CR; Hendrix CW; Celum C; Bangsberg DR; Baeten JM;
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):91-7. PubMed ID: 25118795
[TBL] [Abstract][Full Text] [Related]
11. Impact of Tenofovir gel as a PrEP on HIV infection: a mathematical model.
Rahman SM; Vaidya NK; Zou X
J Theor Biol; 2014 Apr; 347():151-9. PubMed ID: 24380779
[TBL] [Abstract][Full Text] [Related]
12. Antiretroviral prophylaxis: a defining moment in HIV control.
Karim SS; Karim QA
Lancet; 2011 Dec; 378(9809):e23-5. PubMed ID: 21771566
[No Abstract] [Full Text] [Related]
13. Impact of an adherence intervention on the effectiveness of tenofovir gel in the CAPRISA 004 trial.
Mansoor LE; Karim QA; Werner L; Madlala B; Ngcobo N; Cornman DH; Amico KR; Fisher J; Fisher WA; Macqueen KM; Karim SS
AIDS Behav; 2014 May; 18(5):841-8. PubMed ID: 24633717
[TBL] [Abstract][Full Text] [Related]
14. Recruitment of high risk women for HIV prevention trials: baseline HIV prevalence and sexual behavior in the CAPRISA 004 tenofovir gel trial.
Karim QA; Kharsany AB; Frohlich JA; Baxter C; Yende N; Mansoor LE; Mlisana KP; Maarschalk S; Arulappan N; Grobler A; Sibeko S; Omar Z; Gengiah TN; Mlotshwa M; Samsunder N; Karim SS
Trials; 2011 Mar; 12():67. PubMed ID: 21385354
[TBL] [Abstract][Full Text] [Related]
15. Assessing the implementation effectiveness and safety of 1% tenofovir gel provision through family planning services in KwaZulu-Natal, South Africa: study protocol for an open-label randomized controlled trial.
Mansoor LE; Abdool Karim Q; Mngadi KT; Dlamini S; Montague C; Nkomonde N; Mvandaba N; Baxter C; Gengiah TN; Samsunder N; Dawood H; Grobler A; Frohlich JA; Abdool Karim SS
Trials; 2014 Dec; 15():496. PubMed ID: 25527071
[TBL] [Abstract][Full Text] [Related]
16. Tenofovir use and pregnancy among women initiating HAART.
Maskew M; Westreich D; Firnhaber C; Sanne I
AIDS; 2012 Nov; 26(18):2393-7. PubMed ID: 22951630
[TBL] [Abstract][Full Text] [Related]
17. A preemptive strike against HIV.
Willyard C
Nat Med; 2009 Feb; 15(2):126-9. PubMed ID: 19197277
[No Abstract] [Full Text] [Related]
18. Epidemiological impact of tenofovir gel on the HIV epidemic in South Africa.
Williams BG; Abdool Karim SS; Karim QA; Gouws E
J Acquir Immune Defic Syndr; 2011 Oct; 58(2):207-10. PubMed ID: 21654503
[TBL] [Abstract][Full Text] [Related]
19. Should tenofovir ever be used in association with didanosine?
Diaz RS
Braz J Infect Dis; 2005 Dec; 9(6):452-3. PubMed ID: 16410938
[No Abstract] [Full Text] [Related]
20. Topical microbicides--what's new?
Karim QA; Baxter C; Karim SA
J Acquir Immune Defic Syndr; 2013 Jul; 63 Suppl 2():S144-9. PubMed ID: 23764627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
